G1SK34 Stock Overview
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£41.08 |
| 52 Week High | UK£50.15 |
| 52 Week Low | UK£33.33 |
| Beta | 0.33 |
| 11 Month Change | -6.00% |
| 3 Month Change | -10.15% |
| 1 Year Change | 20.12% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 24.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| G1SK34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 0.7% | -3.1% | -1.9% |
| 1Y | 20.1% | -14.8% | -0.3% |
Return vs Industry: G1SK34 exceeded the BR Pharmaceuticals industry which returned -14.8% over the past year.
Return vs Market: G1SK34 exceeded the BR Market which returned -0.3% over the past year.
Price Volatility
| G1SK34 volatility | |
|---|---|
| G1SK34 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in BR Market | 8.6% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: G1SK34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: G1SK34's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| G1SK34 fundamental statistics | |
|---|---|
| Market cap | R$409.31b |
| Earnings (TTM) | R$18.49b |
| Revenue (TTM) | R$230.60b |
22.1x
P/E Ratio1.8x
P/S RatioIs G1SK34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G1SK34 income statement (TTM) | |
|---|---|
| Revenue | UK£31.31b |
| Cost of Revenue | UK£8.65b |
| Gross Profit | UK£22.67b |
| Other Expenses | UK£20.15b |
| Earnings | UK£2.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 72.39% |
| Net Profit Margin | 8.02% |
| Debt/Equity Ratio | 119.4% |
How did G1SK34 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield99%
Payout RatioDoes G1SK34 pay a reliable dividends?
See G1SK34 dividend history and benchmarks| GSK dividend dates | |
|---|---|
| Ex Dividend Date | Nov 13 2024 |
| Dividend Pay Date | Jan 15 2025 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 62 days |
Does G1SK34 pay a reliable dividends?
See G1SK34 dividend history and benchmarks